# Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

> **NCT02118831** · PHASE1,PHASE2 · COMPLETED · sponsor: **California Retina Consultants** · enrollment: 56 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion

## Interventions

- **BIOLOGICAL:** Blood Sample Collection
- **DRUG:** Aflibercept
- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02118831
- **Lead sponsor:** California Retina Consultants
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-02
- **Final completion:** 2014-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118831, "Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02118831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*